Granted Patent
B2
US 7,618,817 · App. 11/178,258 · Granted Nov 17, 2009
Genetically modified human natural killer cell lines
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (FcγRIII-A), or other Fcγ or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as FcεRI-γ, TCR-ζ, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.
Claims (1)
1. A modified NK-92 cell available from American Type Culture Collection as Deposit No. PTA-8837.
Assignments (5)
RELEASE OF SECURITY INTEREST
Recorded Jul 23, 2021
From: CONKWEST, INC.
To: WEISS, ANNIE; DAYAN, RAYMOND; BUXBAUM, GARY; LOWEY, ELIOT; MOSKOVITS, DAVID; SCHLESINGER, MICHAEL; SCHLESINGER, ANDREW; INZLICHT-SPREI, ELI; SCHREIBER, MICHAEL; GOLD, JACOB DAVID; YOMTOV, MENACHEM; RIEDER, RALPH; LANG, HARVEY; EMES FOUNDATION, INC.
Reel/Frame 056970/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 8, 2020
From: THE FOX CHASE CANCER CENTER FOUNDATION
To: THE INSTITUTE FOR CANCER RESEARCH
Reel/Frame 053562/0938 →
CONFIRMATORY LICENSE
Recorded Jan 8, 2014
From: FOX CHASE CANCER CENTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 031936/0166 →
SECURITY AGREEMENT
Recorded Oct 6, 2009
From: ZELLERX CORPORATION
To: MOSKOVITS, DAVID; SCHLESINGER, MICHAEL; ANDREW SCHLESINGER DEFINED BENEFIT PLAN; SPREI, ELI INZLICHT; SCHREIBER, MICHAEL; GOLD, JACOB DAVID; YOMTOV, MENACHEM; RIEDER, RALPH; LANG, HARVEY; LOWEY, ELIOT; BUXBAUM, GARY; WEISS, ANNIE; DAYAN, RAYMOND; EMES FOUNDATION, INC.
Reel/Frame 023332/0107 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 8, 2006
From: CAMPBELL, KERRY S.
To: FOX CHASE CANCER CENTER
Reel/Frame 017276/0710 →